Delta9-tetrahydrocannabinol and cannabidiol modulate hippocampal glutamate dynamics in an animal model of Alzheimer’s disease
Nuria Sánchez Fernández, Laura Gómez-Acero, Francisco Ciruela, Jordi Bonaventura, Ester Aso · FENS Forum 2024
The endocannabinoid system (ECS) has gained attention as a potential target to treat Alzheimer’s disease (AD) due to its neuroprotective, antioxidant, and anti-inflammatory properties. Consequently, natural cannabinoids like delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have emerged as potential drugs against AD. Previous findings from our research group demonstrated that a combination of non-psychoactive doses of THC and CBD mitigates cognitive decline in an AD murine model, the APP/PS1 mice. Cognitive decline in AD is linked to the dysregulation of glutamate transmission within the
ePoster · Neuroscience